McKesson Corporation (MCK)vs111 Inc (YI)
MCK
McKesson Corporation
$879.75
-0.25%
HEALTHCARE · Cap: $108.85B
YI
111 Inc
$6.29
-1.02%
HEALTHCARE · Cap: $58.07M
Smart Verdict
WallStSmart Research — data-driven comparison
McKesson Corporation generates 2830% more annual revenue ($397.96B vs $13.58B). MCK leads profitability with a 1.1% profit margin vs -0.5%. MCK earns a higher WallStSmart Score of 57/100 (C).
MCK
Buy57
out of 100
Grade: C
YI
Avoid31
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+41.2%
Fair Value
$1622.09
Current Price
$879.75
$742.34 discount
Intrinsic value data unavailable for YI.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Large-cap with strong market position
Earnings expanding 38.0% YoY
Generating 1.1B in free cash flow
Conservative balance sheet, low leverage
Safe zone — low bankruptcy risk
Areas to Watch
Moderate valuation
ROE of 0.0% — below average capital efficiency
1.1% margin — thin
Operating margin of 1.6%
0.0% earnings growth
Smaller company, higher risk/reward
ROE of -10.9% — below average capital efficiency
Revenue declined 16.7%
Comparative Analysis Report
WallStSmart ResearchBull Case : MCK
The strongest argument for MCK centers on Debt/Equity, Altman Z-Score, Market Cap. Revenue growth of 11.4% demonstrates continued momentum. PEG of 1.07 suggests the stock is reasonably priced for its growth.
Bull Case : YI
The strongest argument for YI centers on Debt/Equity, Altman Z-Score.
Bear Case : MCK
The primary concerns for MCK are P/E Ratio, Return on Equity, Profit Margin. Thin 1.1% margins leave little buffer for downturns.
Bear Case : YI
The primary concerns for YI are EPS Growth, Market Cap, Return on Equity.
Key Dynamics to Monitor
MCK profiles as a value stock while YI is a turnaround play — different risk/reward profiles.
YI carries more volatility with a beta of 0.64 — expect wider price swings.
MCK is growing revenue faster at 11.4% — sustainability is the question.
MCK generates stronger free cash flow (1.1B), providing more financial flexibility.
Bottom Line
MCK scores higher overall (57/100 vs 31/100) and 11.4% revenue growth. Both earn "Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
McKesson Corporation
HEALTHCARE · MEDICAL DISTRIBUTION · USA
McKesson Corporation is an American company distributing pharmaceuticals and providing health information technology, medical supplies, and care management tools.
Visit Website →111 Inc
HEALTHCARE · MEDICAL DISTRIBUTION · China
111, Inc. operates an integrated online and offline platform in the healthcare market in the People's Republic of China. The company is headquartered in Shanghai, the People's Republic of China.
Visit Website →Compare with Other MEDICAL DISTRIBUTION Stocks
Want to dig deeper into these stocks?